BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.…
BioHarvest Sciences Inc. Common Stock Q3 2026 Earnings Call Summary
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
BioHarvest Sciences (NASDAQ: BHST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 89 employees.
The shares were at 1.300 USD on 20 November 2026, down 83.5% over 52 weeks. Its 52-week range is 0.9118 USD to 8.300 USD: the price is 84.3% below the high and 42.6% above the low.
Its market capitalisation is 29.47M USD.
BioHarvest Sciences reports return on equity of -43.8%, an operating margin of -18.0% and revenue up 3.8% year over year.
It holds more cash than debt, a net cash position of 528.00K USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 31 March 2027.